What is the recommended NA-Selank Amidate dosage?

NA-Selank Amidate dosing varies by experience level. Beginners typically start at 200mcg 2x daily, moderate users at 400mcg 2x daily, and aggressive protocols use 600mcg 3x daily.

How do you reconstitute NA-Selank Amidate?

NA-Selank Amidate comes as a pre-filled device — no reconstitution needed.

What is the half-life of NA-Selank Amidate?

The half-life of NA-Selank Amidate is ~2-3 min (plasma); functional effects persist 6-8 hours via downstream gene expression. This determines how frequently you need to dose for consistent blood levels.

NA-Selank Amidate

CognitiveNasalResearchGrade B~2-3 min (plasma); functional effects persist 6-8 hours via downstream gene expression half-life

NootropicAnxiolyticTuftsin AnalogGABA ModulatorBDNF EnhancerImmunomodulatoryIntranasal4 weeks on / 2 weeks off

Benefits

Anxiolytic effects comparable to low-dose benzodiazepines without sedation, tolerance, or dependence

Upregulates BDNF expression in the hippocampus for enhanced neuroplasticity and memory

Inhibits enkephalin-degrading enzymes, raising endogenous opioid peptide levels

Reduces pro-inflammatory cytokines (IL-6, IL-1-beta, TNF-alpha) under stress conditions

Nootropic effects including improved memory consolidation, attention, and learning speed

Antiasthenic properties — reduces fatigue and improves mental energy

Enhanced enzymatic stability over native Selank due to N-acetylation and C-amidation

Half-Life

~2-3 min

Route

Nasal

Frequency

2x Daily

Vial Sizes

5mg, 10mg

BAC Water

Pre-filled

Safety Grade

Grade B

Open NA-Selank Amidate Dosage Calculator

Calculate exact syringe units for your vial and dose

About NA-Selank Amidate

NA-Selank Amidate is a stabilized derivative of Selank, itself a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). The N-terminal acetylation and C-terminal amidation modifications protect the peptide from rapid degradation by aminopeptidases and carboxypeptidases, extending its functional half-life after intranasal delivery. NA-Selank Amidate acts through multiple converging mechanisms: positive allosteric modulation of GABA-A receptors (producing anxiolytic effects comparable to low-dose benzodiazepines without sedation or dependence), inhibition of enkephalin-degrading enzymes (raising endogenous enkephalin levels), upregulation of BDNF expression in the hippocampus, and modulation of pro-inflammatory cytokines including IL-6, IL-1-beta, and TNF-alpha. Clinical trials of the parent compound Selank in patients with generalized anxiety disorder demonstrated efficacy comparable to medazepam, with additional antiasthenic and mild nootropic properties not seen with benzodiazepine comparators.

Who Should Consider NA-Selank Amidate

Adults with generalized anxiety disorder seeking non-benzodiazepine anxiolytic options
Individuals experiencing chronic stress with associated cognitive impairment
Those seeking nootropic support for memory, focus, and learning without stimulant side effects
People with stress-related immune dysregulation or elevated inflammatory markers
Individuals looking for an anxiolytic without sedation, tolerance, or dependence risk
Those recovering from chronic alcohol-related cognitive impairment

How NA-Selank Amidate Works

NA-Selank Amidate operates through four primary pathways. First, it acts as a subtype-selective, concentration-dependent positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission without directly binding the benzodiazepine site — this accounts for its anxiolytic effects without sedation or dependence. Second, it potently inhibits enkephalin-degrading enzymes (enkephalinases) in blood plasma with an IC50 of approximately 15 micromolar, thereby raising endogenous enkephalin levels and contributing to mood stabilization and analgesia. Third, intranasal administration regulates BDNF mRNA and protein expression in the hippocampus, promoting synaptic plasticity, memory consolidation, and neuroprotection. Fourth, Selank-derived peptides modulate the expression of over 30 inflammation-related genes in immune tissue, reducing concentrations of pro-inflammatory cytokines (IL-1-beta, IL-6, TNF-alpha) while restoring anti-inflammatory IL-4 levels — this dual neuro-immune mechanism underlies its stress-protective properties.

What to Expect

First dose

20-60 min

Rapid onset of mild anxiolytic effects within 20-40 minutes of intranasal administration. Subtle sense of calm and reduced mental tension. Some users report improved mental clarity and verbal fluency within the first hour. Effects peak at 1-2 hours post-dose.

Days 1-3

Anxiolytic effects become more consistent with regular dosing. Reduced reactivity to daily stressors. Mild improvements in focus and attention. Sleep quality may improve as baseline anxiety decreases.

Days 4-7

Nootropic effects emerge — improved memory recall, faster information processing, and better sustained attention. BDNF upregulation is underway. Mood stabilization and reduced irritability become more noticeable.

Weeks 2-4

Full anxiolytic and nootropic benefits develop. Significant reduction in generalized anxiety comparable to low-dose benzodiazepines. Enhanced learning capacity and memory consolidation. Immunomodulatory effects (reduced inflammatory cytokines) contribute to improved overall well-being and stress resilience.

After cycling off

Anxiolytic effects persist for approximately 5-7 days after the last dose. Cognitive improvements driven by BDNF-mediated neuroplasticity may persist longer. No withdrawal symptoms, rebound anxiety, or dependence reported. Cycle can be repeated after a 2-week break.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	200mcg	2x Daily
Moderate	400mcg	2x Daily
Aggressive	600mcg	3x Daily

Note: N-acetylated, C-amidated analog of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro). The acetyl and amide modifications improve enzymatic stability and nasal membrane permeability compared to native Selank. Administered intranasally as a pre-mixed nasal spray — no reconstitution needed. Approved in Russia as an anxiolytic for GAD and neurasthenia under the parent Selank formulation.

How to Inject NA-Selank Amidate

Administer intranasally using a calibrated nasal spray device. Typical dose is 200-600 mcg per nostril, 2-3 times daily. Clear nasal passages before administration. Tilt head slightly forward, insert spray tip into one nostril, and depress once while gently inhaling. Alternate nostrils between doses. Onset of anxiolytic effects occurs within 20-40 minutes, peaking at 1-2 hours. Avoid blowing nose for 10-15 minutes after application. NA-Selank Amidate typically comes as a pre-mixed intranasal solution; if using lyophilized powder, reconstitute with bacteriostatic water to the desired concentration.

Cycling Protocol

On Period

4 weeks

Off Period

2 weeks

Russian clinical protocols for Selank use 14-day treatment courses intranasally 3 times daily. Many practitioners extend this to 4-week cycles with 2-week washout periods. The anxiolytic effect has been reported to persist for approximately one week after the last dose. No tolerance or dependence has been observed with repeated cycles. Some users employ continuous low-dose use (200 mcg 1-2x daily) without cycling.

Pharmacokinetics

Half-Life

3min

Bioavailability

Intranasal: rapid absorption through nasal mucosa with detectable plasma levels within 15-30 minutes

Tmax

~20-40 min (intranasal); peak effects at 1-2 hours

Data Confidence

moderate

Source: Plasma t½ ~2-3 minutes for native Selank. NA-Selank Amidate has improved enzymatic stability due to N-acetylation and C-amidation, likely extending effective t½ somewhat. Functional anxiolytic and nootropic effects persist 6-8 hours due to downstream gene expression changes (BDNF upregulation, cytokine modulation) and enkephalinase inhibition.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Generally very well tolerated. Mild nasal irritation or transient burning at the application site. Occasional mild fatigue or drowsiness in sensitive individuals. Brief transient drop in blood pressure (observed in animal studies, typically 1-3 minutes post-dose). No reports of dependence, withdrawal, amnesia, or sedation in clinical trials of the parent compound. No significant toxicity observed in studies lasting up to one month of daily administration.

Contraindications

Pregnancy or breastfeeding — no safety data available
Known hypersensitivity to Selank, tuftsin, or any component of the formulation
Severe hypotension — transient blood pressure reduction observed in animal models
Active nasal infections, nasal polyps, or recent nasal surgery — may impair absorption
Children under 18 — not studied in pediatric populations
Autoimmune conditions — immunomodulatory effects may theoretically alter immune balance

Drug Interactions

Benzodiazepines (diazepam, alprazolam, lorazepam) — Selank enhances diazepam effects in preclinical models; may potentiate sedation if combined at higher doses
Antihypertensives — additive blood pressure lowering possible given Selank's transient hypotensive effect in animal studies
Opioid analgesics — Selank inhibits enkephalinase and may alter endogenous opioid peptide levels; theoretical interaction
Immunosuppressants (cyclosporine, tacrolimus) — Selank modulates cytokine expression and immune gene activity; may alter immunosuppressive balance
GABAergic drugs (gabapentin, pregabalin, barbiturates) — potential for additive CNS depressant effects via GABA-A modulation
Alcohol — may counteract nootropic and neuroprotective effects; avoid concurrent use